Navigation Links
MediciNova Announces Positive Clinical Results From MN-166 Phase II,Multiple Sclerosis Trial

al MRI scans over 12 months of treatment was observed in patients treated with MN-166 compared to placebo, which was the protocol-defined primary endpoint of the study. No clinical or radiological benefit was observed in patients treated with 30 mg per day of MN-166. MN-166 was well tolerated at all doses in this trial. Eighty-nine percent of patients completed the first 12 months of the trial with only mild gastrointestinal side effects observed with MN-166 compared to placebo (3-6% vs. 1-3%, respectively).

The independent Data Safety Monitoring Board (DSMB) has recommended that the trial continue beyond the first year of treatment without modification and was supportive of further clinical evaluation of MN-166 in MS patients.

"We are pleased with the benefit of MN-166 observed in MS patients in this trial; they confirm the results of previous pilot trials of MN-166 in MS patients conducted by Japanese academic investigators," said Yuichi Iwaki, M.D., Ph.D., Executive Chairman and CEO of MediciNova, Inc. "The divergence of clinical benefit and radiological findings suggest that MN-166 may be acting by a different mode of action than current treatments. We will carefully analyze the clinical data with our independent advisors to determine next steps in the development program and to advance this compound into Phase III clinical testing."

In July 2005, MediciNova initiated a randomized, double-blind, placebo-controlled multi-center Phase II clinical trial of MN-166 in MS patients in five Eastern European countries. A total of 297 patients with at least one gadolinium-enhancing lesion on a screening visit MRI scan were randomized to receive placebo or one of two doses of MN-166 (30 or 60 mg per day) in this trial. Safety and efficacy assessments were performed at months 1, 2, 4, 6, 8, 10 and 12 of the trial. Efficacy assessments were based on the evaluation of the cumulative number of active (gadolinium-enhancing (T1) and non-enhancing new/enlargi
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:4/17/2015)... ADELAIDE, Australia , April 17, 2015 ... the discovery and development of innovative therapeutics for the ... system, today announced the presentation of data from three ... American Association for Cancer Research (AACR) 106 th ... Philadelphia, PA USA. ...
(Date:4/16/2015)... , April 16, 2015  Hologic, Inc. ... cervical cancer screening study i published on-line ... peer-reviewed journal of the American Cancer Society. ... and the University of Pittsburgh Medical Center, supports current consensus ... recommend that women 30-65 years of age be ...
(Date:4/16/2015)... , April 16, 2015  Diplomat Pharmacy, Inc. ... Shannon Beltrand to their senior leadership team as ... be responsible for securing and properly monitoring Diplomat,s data, ... both internally and externally. Additionally, she will play key ... "We are very excited to have someone ...
Breaking Medicine Technology:Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 2Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 4Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 5Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 2Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 3Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 4Diplomat Names Shannon M. Beltrand as New CISO 2
(Date:4/18/2015)... Patients who undergo radiation for a hematologic cancer ... but the disease is likely to differ in some ... Surviving Mesothelioma has just posted the details of this ... read it now. , Scientists from China, the ... who had both a hematologic cancer (like lymphoma or ...
(Date:4/18/2015)... More than 2000 styles of newly designed prom ... online store carrying celebrity inspired special occasion dresses. With ... perfect dresses for their prom. For those who are ... TheCelebrityDresses.com would be an ideal choice. , "We ... inspired by the most loved styles seen at this ...
(Date:4/18/2015)... 18, 2015 “ ArcAngel ” was featured ... a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... safety app. , In a turbulent world, people may ... 911 should always be their first move, but some situations ...
(Date:4/17/2015)... (PRWEB) April 18, 2015 Heritage Woods ... begin its Supportive Living Week Celebration on April 20 ... having a healthy mind, body and soul. , The ... McLeansboro, Illinois, serves older adults of all incomes, including ... their independence. , Supportive Living Week is observed every ...
(Date:4/17/2015)... ERGO-Pedic Products, LLC, which produces therapeutic ... products to help a broader range of people plagued ... the second most common visitors to doctors. , “The ... to help relieve sitting pain. Then, only a couple ... happy customers later, we began getting questions from those ...
Breaking Medicine News(10 mins):Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2
... second leading cause of hospitalization of elderly patients. In many ... complete decline in the patient,s health, setting off a long ... published in the April 2010 issue of The Journal ... person,s pre-surgical health classificationas determined by the American Society of ...
... ... Says Empire Blue Cross Puts Stockholders Ahead of Community Healthcare. As Other Health ... ... said today that its contract with Empire Blue Cross Blue Shield expired at midnight ...
... in Hong Kong and South Korea released results from ... transplantation (LDLT). A single paired exchange, performed by ... success. The Korean team reported 16 donor exchanges ... of this novel approach to organ transplantation appear in ...
... ... in real-time a key differentiator , ... Marlborough, MA (PRWEB) April 1, 2010 -- LogMatrix, a provider of log management, threat ... is currently using the LogMatrix LogCenter solution to capture and report on over 2 billion ...
... a world first study of its kind, 161 postnatal ... two separate groups to test the effect of a ... The experimental group received an eight-week "Mother and Baby" ... physiotherapist combined with parenting education. In the ...
... fibers before age 36 raises women,s odds of developing cancer, ... exposure to chemicals and pollutants before a woman is in ... after menopause, a new study has found. , The study ... they were between the ages of 50 and 75, and ...
Cached Medicine News:Health News:Hip surgery success partially predicted by number of other existing conditions 2Health News:Community Hospital Group Contract Expires With Major Health Plan Insurer 2Health News:Community Hospital Group Contract Expires With Major Health Plan Insurer 3Health News:Living donor exchange poses new option for liver transplantation 2Health News:LogMatrix Log Management Solution Easily Supports Customer's Extreme Scalability and Data Retrieval Requirements 2Health News:New mums beat the blues and increase wellbeing with physio exercise, study reveals 2Health News:Workplace Chemicals May Boost Breast Cancer Risk 2
... BioZip Suture Anchor is a unique double loaded ... is made from Poly-L Lactic Acid (PLLA) and ... are attached to the suture ends for open ... repairs. The trocar tip inserter allows insertion with ...
... LactoSorb copolymer is an absorbable ... L-Lactic acid and 18% glycolic acid. ... such as 100% poly-L-lactic acid (PLLA) ... copolymer is substantially amorphous (without crystallinity), ...
... is an absorbable co-polymer synthesized from ... 18% glycolic acid. Unlike the homopolymers ... poly-L-lactic acid (PLLA) or 100% poly-glycolic ... amorphous (without crystallinity), meaning that its ...
... The USS Sports Medicine™ POLYSORB™ Soft Tissue Anchor ... to attach soft tissue to bone using sutures. ... prepared hole in the bone, and is used ... are made of a resorbable copolymer, derived from ...
Medicine Products: